Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms
This study has been completed.
First Posted: August 1, 2008
Last Update Posted: September 26, 2008
Information provided by:
The purpose of this study is to compare the safety and efficacy of USL-221 to placebo for postmenopausal patients.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients|
Resource links provided by NLM:
Drug Information available for: Estradiol Estradiol cypionate Estradiol valerate Estradiol acetate Estradiol hemihydrateU.S. FDA Resources
Further study details as provided by Upsher-Smith Laboratories:
Contacts and Locations
No Contacts or Locations Provided